Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ITGB2-derived neoantigen vaccine
- Development stage
- Unknown
- Lead developer
- Sichuan Cancer Hospital
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The ITGB2-derived neoantigen vaccine is an experimental personalized cancer immunotherapy developed by Sichuan Cancer Hospital for the treatment of hepatocellular carcinoma (HCC). This vaccine targets specific neoantigens arising from mutations in the ITGB2 (Integrin Subunit Beta 2) gene, which are identified within the patient's tumor. By administering these tumor-specific peptides, the therapy aims to stimulate the patient's immune system, particularly activating CD8+ and CD4+ T cells to recognize and eliminate cancer cells expressing the ITGB2 neoantigen. This precision oncology approach is designed to provide a targeted anti-tumor response while minimizing off-target effects on healthy tissues. It is currently being evaluated in early-phase clinical trials to assess its safety and immunogenicity in patients with advanced or recurrent HCC.
- Other names
- ITGB2 neoantigen vaccineITGB-2 neoantigen vaccineITGB 2 neoantigen vaccine
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on ITGB2-derived neoantigen vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ITGB2-derived neoantigen vaccine.